Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Results 1 - 20 of 368 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

1
Member Avatar drugtrader (92.31) Submitted: 8/7/2015 11:26:32 AM : Underperform Start Price: $3.42 EXEL Score: -81.16

Be careful fellow fools...this could be a final pump before the last(?) dump. Just be cautious, I hope the drug isn't a total failure good luck...

Recs

1
Member Avatar NHWeston102 (23.19) Submitted: 7/22/2015 1:33:54 PM : Outperform Start Price: $6.34 EXEL Score: +1.78

The same drug that brought EXEL low because it worked poorly on one cancer now appears about to take the company higher based on good reports against kidney cancer. Kidney medicines are always winners.

Recs

0
Member Avatar SnowMan9890 (65.94) Submitted: 6/14/2015 9:05:08 PM : Outperform Start Price: $3.56 EXEL Score: +75.61

Solely based on speculation in their cancer drugs, looking to track and see what happens.

Recs

0
Member Avatar StockMarketKid13 (70.92) Submitted: 6/13/2015 3:53:33 PM : Outperform Start Price: $3.56 EXEL Score: +75.61

This is an amazing stock on the rise that will gain much in years to come

Recs

0
Member Avatar bkinvest (36.47) Submitted: 6/12/2015 11:10:29 AM : Outperform Start Price: $3.49 EXEL Score: +79.62

Good entry point with 2 cancer fighting drugs in the pipeline with fast track FDA approval.

Recs

0
Member Avatar sana5000 (60.16) Submitted: 1/7/2015 11:08:45 AM : Outperform Start Price: $1.62 EXEL Score: +278.11

exel

Recs

0
Member Avatar Scrappyq99 (< 20) Submitted: 10/9/2014 2:03:43 PM : Outperform Start Price: $1.53 EXEL Score: +294.33

It has nowhere to go but up. It has been beaten up after the latest trial news with some of it being positive. Still has a few things in the pipeline.

Recs

0
Member Avatar rnisco (< 20) Submitted: 9/30/2014 9:14:55 PM : Underperform Start Price: $1.58 EXEL Score: -284.19

exel is now tainted and will remain so for the foreseeable future. Put your money into something that will grow. Do not just hang on-take your losses and turn them into a gain with a much better rated company.

Recs

0
Member Avatar usubanas (99.74) Submitted: 9/3/2014 12:18:53 PM : Outperform Start Price: $1.89 EXEL Score: +222.94

I thought plunge to $4 was a great buying opportunity. Now plunge to $2 again great? I expect RCC data in 2015 to finally move this thing up.

Recs

0
Member Avatar asilverp (63.52) Submitted: 9/2/2014 7:43:18 PM : Underperform Start Price: $1.85 EXEL Score: -230.29

Falling on unusual volume, not a good sign.

Recs

0
Member Avatar Strixx (78.68) Submitted: 8/15/2014 2:41:21 PM : Outperform Start Price: $4.22 EXEL Score: +42.52

I do not own this stock, but am strongly considering it.

Recs

1
Member Avatar RayJay111 (< 20) Submitted: 7/22/2014 1:40:52 AM : Outperform Start Price: $3.62 EXEL Score: +67.65

This is a stock for an investor with a long range purview. With a variety of drugs and treatments nearing the clinical trials stage it should be a clear cut winner in 3-5 years.

Recs

0
Member Avatar marsuculix (55.52) Submitted: 7/15/2014 4:20:46 AM : Outperform Start Price: $4.08 EXEL Score: +48.54

I missed the boat - but run-up will continue as long as takeover rumors are spreading...

Recs

2
Member Avatar topinch (< 20) Submitted: 7/3/2014 8:03:18 PM : Outperform Start Price: $3.61 EXEL Score: +68.02

There are several things affecting the performance here, earlier when there was a possibility of this company finishing third trials early stock shot up to 8 with analysts expecting higher, they annouce trials will continue, stock returns down to 3 to 4 range, trials are scheduled to end in nov, dec, no reason not to expect this one to return to being north of 7.

Recs

1
Member Avatar Estrogen (52.91) Submitted: 5/24/2014 2:54:48 PM : Outperform Start Price: $4.75 EXEL Score: -57.50

stock have taken a drumming, but still has good pipeline and partnerships. At this level, buy, buy buy, and take your profits on a double.

Recs

0
Member Avatar TerryFool (55.77) Submitted: 4/27/2014 1:59:46 PM : Outperform Start Price: $3.37 EXEL Score: +74.24

SPEC BUY@ 3.25 TP 14

Recs

0
Member Avatar jtallenmd (99.78) Submitted: 4/23/2014 1:01:45 PM : Outperform Start Price: $3.45 EXEL Score: +70.17

Doubling down after ending a losing pick.

Recs

1
Member Avatar peregrine (99.08) Submitted: 4/8/2014 8:58:33 PM : Outperform Start Price: $3.61 EXEL Score: +60.69

An independent data monitoring committee recommended COMET-1 phase 3 trial involving Cometriq in metastatic castration-resistant prostate cancer (mCRPC) to proceed to its final analysis. Most biotechs would shoot up on this news because it verifies the safety and potential efficacy of the therapy, yet EXEL shares crashed on the news. The fall in the share price was classic overreaction with severe manipulation to shake out retail investors, on the excuse that the street was hoping for the trial to be stopped early for efficacy. This is an extremely high expectation for any biotech, and should have barely moved the shares to the downside at all. On top of this EXEL has an extremely strong pipeline, nice partnerships, strong cash position, with some very nice upcoming catalysts this year. One doesn't see buying opportunities like this often, and I would not be surprised to see shares trading north of $8 as shares reach a fair valuation prior to the next data release on COMET-1. EXEL at its current valuation is only being valued at one time peak sales, when most other biotech are valued at three to five times annual peak sales estimates. In other words, it would not be a stretch at all for shares to move to above $11.25 before COMET-1 data update is even released.

Recs

0
Member Avatar g60 (57.38) Submitted: 4/1/2014 1:36:29 AM : Outperform Start Price: $3.67 EXEL Score: +59.79

Plenty of catalysts this year. After the over reaction on the interim results, happy to get in at multi-year lows.

Recs

0
Member Avatar Crystalball (96.07) Submitted: 3/31/2014 9:45:32 AM : Outperform Start Price: $4.01 EXEL Score: +44.90

Big upside to this biotech. The recent decline was only due to the common announcement that the company's clinical trial of cancer therapy cabozantinib's use in treating prostate cancer will continue beyond its interim point. Big upside on this one -- even before the completion of the trial.

Featured Broker Partners


Advertisement